Publication | Closed Access

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Breast OncologySingle-agent LapatinibMedicineProof-of-concept StudyPathologyBreast CancerCell BiologyCancer TreatmentOncologyRadiation OncologyMolecular OncologyFinal Results